Last reviewed · How we verify
nirmatrelvir-ritonavir
nirmatrelvir-ritonavir is a Protease inhibitor Small molecule drug developed by Pfizer. It is currently FDA-approved for Treatment of mild to moderate COVID-19 in adults and pediatric patients (5 years of age and older) who weigh at least 40 kg..
Nirmatrelvir-ritonavir, developed by Pfizer Inc., is a small molecule used to treat mild to moderate COVID-19 in adults and pediatric patients. It works by inhibiting the SARS-CoV-2 protease enzyme. This mechanism allows for the reduction of viral replication and subsequent symptoms. The drug has shown significant clinical differentiation in its efficacy and safety profile. Commercially, nirmatrelvir-ritonavir has been a highly significant revenue generator, with $63.6 billion in revenue. The drug's pipeline developments are focused on expanding its indications and improving its formulation.
At a glance
| Generic name | nirmatrelvir-ritonavir |
|---|---|
| Sponsor | Pfizer |
| Drug class | Protease inhibitor |
| Target | SARS-CoV-2 protease enzyme |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Treatment of mild to moderate COVID-19 in adults and pediatric patients (5 years of age and older) who weigh at least 40 kg.
Common side effects
- Impaired sense of taste / Bitterness
- Dysgeusia
- Diarrhea
- Diarrhoea
- Nausea
- Headache
- Muscle aches
- dysgeusia
- Taste disorder
- COVID-19
- diarrhoea
- Fibrin D dimer increased
Drug interactions
- Atorvastatin
- Buprenorphine
- Cyclosporine
- Digoxin
- Ergot alkaloids
- Fentanyl
- HMG-CoA reductase inhibitors (e.g., simvastatin)
- Lopinavir/ritonavir
- Midazolam
- Pimozide
- Prazosin
- Rifampicin
Key clinical trials
- RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms (PHASE2)
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial (PHASE2)
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients (PHASE2)
- Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
- A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
- Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 (PHASE2)
- AGILE (Early Phase Platform Trial for COVID-19) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nirmatrelvir-ritonavir CI brief — competitive landscape report
- nirmatrelvir-ritonavir updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about nirmatrelvir-ritonavir
What is nirmatrelvir-ritonavir?
What is nirmatrelvir-ritonavir used for?
Who makes nirmatrelvir-ritonavir?
What drug class is nirmatrelvir-ritonavir in?
What development phase is nirmatrelvir-ritonavir in?
What are the side effects of nirmatrelvir-ritonavir?
What does nirmatrelvir-ritonavir target?
Related
- Drug class: All Protease inhibitor drugs
- Target: All drugs targeting SARS-CoV-2 protease enzyme
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Treatment of mild to moderate COVID-19 in adults and pediatric patients (5 years of age and older) who weigh at least 40 kg.
- Compare: nirmatrelvir-ritonavir vs similar drugs
- Pricing: nirmatrelvir-ritonavir cost, discount & access